Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 19c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.07), $0.19 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $19.53 million versus the consensus estimate of $18.37 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Kepler Cheuvreux Downgrades Telecom Italia SpA (TIT:IM) (TI) to Hold